Arrowhead Research Corp (ARWR) was Initiated by Chardan Capital Markets to “Buy” and the brokerage firm has set the Price Target at $12. Chardan Capital Markets advised their investors in a research report released on May 19, 2016.
On the company’s financial health, Arrowhead Research Corp reported $-0.27 EPS for the quarter, based on the information available during the earnings call on Aug 4, 2015. Analyst had a consensus estimate of $. The company had revenue of $.13 million for the quarter.The company’s revenue was up 195.5% compared to the same quarter last year.
Arrowhead Research Corp closed down -0.14 points or -2.68% at $5.09 with 8,24,077 shares getting traded on Monday. Post opening the session at $5.24, the shares hit an intraday low of $5.08 and an intraday high of $5.4396 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
In a different news, on Jan 4, 2016, Kenneth Allen Myszkowski (Chief Financial Officer) sold 23,347 shares at $6.13 per share price. According to the SEC, on Jan 14, 2015, Mauro Ferrari (director) purchased 2,300 shares at $6.90 per share price. On Jan 7, 2015, David L. Lewis (Chief Scientific Officer) sold 15,000 shares at $8.01 per share price, according to the Form-4 filing with the securities and exchange commission.
Arrowhead Research Corporation is a biopharmaceutical company. The Company is engaged in developing RiboNucleic Acid interference (RNAi) therapeutics. The Company’s products include ARC-520 ARC-521 ARC-AAT ARC-F12 ARC-HIF2 and ARC-LPA. ARC-520 is an RNAi-based therapeutic designed to treat chronic hepatitis B virus (HBV) infection. ARC-AAT is an unlocked nucleobase analog-containing RNAi-based therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. Its Dynamic Polyconjugate platform is an RNAi delivery system that promotes high levels of target gene knockdown. ARC-F12 is an RNAi-based therapeutic designed to reduce the production of factor 12 with the goal of providing a prophylactic treatment for hereditary angioedema and thromboembolic diseases. ARC-LPA is an RNAi-based therapeutic designed to reduce production of apolipoprotein A. ARC-HIF2 is an RNAi-based therapeutic designed to reduce the production of hypoxia-inducible factor 2a.